Goldline Pharmaceutical's IPO demonstrated unprecedented investor demand on its final day of bidding, achieving 211.41 times subscription as of 11:54 am on Thursday, May 14. According to BSE data, investors bid for 38,68,89,000 shares against the total offer of 18,30,000 shares, resulting in 24,157 applications across all categories. The retail investors' portion was subscribed 264.47 times, while the non-institutional investor category was booked 365.75 times and the qualified institutional buyers segment saw 11.52 times subscription. This exceptional response demonstrates robust investor confidence in the pharma products marketing company's growth prospects and strong market appetite for the issue.
The grey market premium (GMP) has surged to ₹25 on May 14, indicating a substantial listing gain of more than 55% ahead of the market debut. Based on the upper end of the price band of ₹43 per share, the estimated listing price stands at ₹68 per share, implying a potential gain of 58.14% on listing. This represents a significant increase from the earlier grey market premium of ₹17 on May 12, suggesting growing investor optimism about the company's market debut. The shares are set to debut on the BSE SME platform with a tentative listing date of May 19, with share allotment expected to be finalized on May 15.
Goldline Pharmaceutical operates as a pharma products marketing company selling products under the in-house 'Goldline' brand across five different pharmaceutical categories. The company follows an asset-light business strategy, outsourcing manufacturing to 15 contract manufacturers instead of running its own production facilities. Distribution is handled through a network of 7 distributors, with the company generally offering a credit period of up to 60 days. The business has established presence across Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. The company raised ₹3.14 crore from anchor investors ahead of the IPO opening, with Upsurge Opportunities Fund and Vikasa India EIF I Fund - Share Class P allotting 7.32 lakh shares.
Goldline Pharmaceutical has demonstrated steady revenue growth over recent years, with revenue from operations increasing from ₹19.85 crore in FY2023 to ₹23.57 crore in FY2024, before rising further to ₹28.06 crore in FY2025. For the nine months ended December 31, 2025, the company reported revenue of ₹21.41 crore. The company witnessed a strong improvement in profitability, with its profit after tax (PAT) margin expanding sharply from 1.31% in FY2023 to 10.09% in FY2025. The company plans to utilize ₹8.35 crore from the IPO proceeds towards repayment of certain borrowings, while the remaining funds will be used for general corporate purposes. As of March 2026, the company's total outstanding borrowings amounted to ₹9.13 crore, making the IPO proceeds crucial for debt reduction.
Goldline Pharmaceutical's IPO is structured as a book-built issue of ₹11.61 crore, consisting entirely of a fresh issue of 27 lakh shares with a price band fixed between ₹41 and ₹43 per share. The minimum lot size for retail investors is 3,000 shares, requiring a minimum investment of ₹2.58 lakh for two lots, while HNI investors must apply for at least three lots (9,000 shares) amounting to ₹3.87 lakh. The issue is managed by Cumulative Capital Pvt. Ltd. as the book-running lead manager, Bigshare Services Pvt. Ltd. as the registrar, and Nirman Share Brokers Pvt. Ltd. as the market maker. The company's portfolio spans multiple therapeutic segments, with Goldline Pharma offering 42 products in orthopaedics, ENT, gastroenterology, neurology, urology and surgery, while Goldline Cardinal provides 54 products for physicians and specialists.
